Find a clinical trial
Peripheral Venous Thrombosis, Peripheral Arterial Thrombosis
JETi Hong Kong Post Market Study (PMS)
The JETi Hong Kong PMS is a single-arm, multicenter study to collect real-world data on the safety, performance, and clinical benefits of the JETi System for the treatment of acute and subacute thrombosis in the peripheral…
- Conditions
- Peripheral Venous Thrombosis, Peripheral Arterial Thrombosis, Peripheral Arteriovenous Thrombosis
- Trial name
- NCT06340763
- Testing
- JETi Hydrodynamic Thrombectomy System
- Where
- 4 sites in Hong Kong
- Volunteers
- 12 people
- Sponsor
- Abbott Medical Devices
Basal Blood Flow
A Study of a Device Used to Take Pictures of Skin Blood Flow
The purpose of this study is see fi the hyperspectral camera system (HCS) can measure skin blood flow (perfusion and oxygenation) in healthy people.
- Trial name
- NCT03912376
- Testing
- Quest Hyperspectral Imaging System
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cervical Spondylotic Myelopathy
Postural Stability in Cervical Spinal Myelopathy
Veterans are at heightened risk of developing cervical spondylotic myelopathy (CSM) from rigors of military service. Balance and posturography are negatively affected in CSM, but require expensive equipment, and extensive…
- Trial name
- NCT03810781
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Breast Cancer
TARGeted Intraoperative radioTherapy With INTRABEAM as a Boost for Breast Cancer - A Quality Control Registry
Quality Control Registry for IORT used as an anticipiated boost with 20 Gy at the applicator surface followed by EBRT
- Trial name
- TARGIT_BQR (NCT01440010)
- Testing
- IORT with 20 Gy
- Where
- Germany
- Volunteers
- 1,133 people
- Sponsor
- Universitätsmedizin Mannheim
Advanced Hepatocellular Carcinoma
Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
Hepatocellular carcinoma (HCC) is one of the most frequent causes of cancer-related deaths globally and in Korea. Many patients diagnosed at advanced stage, and systemic therapy is mainstay of treatment in patients with advanced…
- Trial name
- NCT04862949
- Testing
- Atezolizumab plus bevacizumab
- Where
- South Korea
- Volunteers
- 131 people
- Sponsor
- CHA University
Prostate Cancer
Description of Relugolix Use in Patients With Prostate Cancer Within the VHA
The purpose of this real-world study is the learn about the demographics and clinical characteristics of patients with prostate cancer who initiated relugolix
- Trial name
- NCT06462014
- Testing
- Relugolix
- Where
- United States
- Volunteers
- 507 people
- Sponsor
- Pfizer
Child, Preschool, Child
Monitoring Activity And Gait In Children
COHORT A: To study whether a digital health tool called Actigraph can be used to collect information on gait and physical activity in healthy children aged 3-17.
- Conditions
- Child, Preschool, Child, Adolescent
- Trial name
- MAGIC (NCT04823650)
- Testing
- COHORT A: Actigraph, Panoramic Bracelet and GENEActiv
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Pfizer
Breast Cancer
Evaluation of Efficiency in Cancerology of New Technologies as Telemedicine and Conected Objects (e-DomSanté)
Observational study about patients treated for a metastasis breast cancer who live far from their comprehensive cancer center and followed by telemedicine, connected watches and patient-reported symptom monitoring.
- Trial name
- e-DomSanté (NCT03359759)
- Testing
- Conected objects
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Institut Bergonié
Gastro Intestinal Stromal Tumor
Patterns of Care and Outcomes of Patients With METAstatic Gastrointestinal Stromal Tumors (METAGIST)
Gastro intestinal stromal tumors (GIST) are rare mesenchymal tumors of the gastrointestinal tract characterized by somatic mutations in the gene encoding the KIT or the PDGFR alpha protein1.
- Trial name
- METAGIST (NCT03963544)
- Testing
- oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR as per recommendations
- Where
- France
- Volunteers
- 492 people
- Sponsor
- Institut Bergonié
Metastatic Breast Cancer
Survival Endpoints in Women Treated for Metastatic Breast Cancer: Contribution of Real-life Databases
Overall survival (OS) is considered the most reliable cancer endpoint and used by the Health Rregulatory authorities (HRA). OS presents multiple advantages in cancer randomized controlled trials (RCT): it is universally accepted…
- Trial name
- NCT03676257
- Testing
- Chemotherapy (exclusive), Endocrine therapy (exclusive), Combination of endocrine therapy and chemotherapy
- Where
- France
- Volunteers
- 20,033 people
- Sponsor
- Institut Bergonié
Metastatic Bone Tumor
Patterns of Care and Outcomes in Patients With Metastatic Bone Tumors (METABONE)
Bone tumors make up about 3-5% of childhood cancers and less than 1% of cancers in adults. Of these, osteosarcoma (OSS) is the most commonly diagnosed primary malignant bone tumor.
- Trial name
- METABONE (NCT03963531)
- Testing
- Any cancer treatment
- Where
- France
- Volunteers
- 545 people
- Sponsor
- Institut Bergonié
Metastatic Breast Cancer
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.
The purpose of this study is to understand the treatment patterns, patients and their clinical outcomes in a real life setting in Israel.
- Trial name
- NCT04671615
- Testing
- palbociclib
- Where
- Israel
- Volunteers
- 559 people
- Sponsor
- Pfizer
Polycystic Kidney, Autosomal Dominant
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
The purpose of this study is to evaluate the safety and effectiveness of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) in the real world clinical setting in Japan.
- Trial name
- NCT02847624
- Testing
- tolvaptan
- Where
- Japan
- Volunteers
- 1,802 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Cancer
Definition for the Assessment of Time-to-event Endpoints in CANcer Trials (DATECAN-1)
In randomised phase III cancer clinical trials, the most objectively defined and only validated time-to-event endpoint is overall survival (OS).
- Trial name
- DATECAN-1 (NCT03676010)
- Testing
- Sarcoma and GIST, Breast cancer, Pancreatic cancer
- Where
- 3 sites in France
- Volunteers
- 265 people
- Sponsor
- Institut Bergonié
Breast Cancer
Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole
This is a retrospective, multicenter, observational study in Japan. The primary objective is to evaluate overall survival (OS) in Japanese patients with HR+/HER2- advanced breast cancer who have been treated with palbociclib plus…
- Trial name
- NCT04735367
- Testing
- palbociclib plus letrozole
- Where
- 13 sites in Japan
- Volunteers
- 42 people
- Sponsor
- Pfizer
HIV, Metabolic Syndrome
Incidence of HANA Conditions in HIV-infected Individuals
With the availability of effective anti-retroviral therapy, HIV-infected individuals are expected not to die of AIDS and have longer life expectancy.
- Conditions
- HIV, Metabolic Syndrome, Osteopenia, Osteoporosis
- Trial name
- NCT03483584
- Where
- Hong Kong
- Volunteers
- 215 people
- Sponsor
- Chinese University of Hong Kong
Invasive Aspergillosis, Mucormycosis
A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
This is a non-interventional medical chart review study aiming to examine the effectiveness, safety, and treatment patterns of isavuconazole in 5 European countries (France, Germany, Italy, Spain, and United Kingdom).
- Trial name
- PRISMA (NCT04550936)
- Testing
- Isavuconazole
- Where
- 15 sites in France, Germany and 3 more
- Volunteers
- 307 people
- Sponsor
- Pfizer
Acute Lymphocytic Leukemia
BESPONSA Injection 1 mg Special Investigation
The purpose of this study is to learn about the safety and effectiveness of BESPONSA. BESPONSA is approved for treatment of relapsed or refractory CD22-positive acute lymphocytic leukemia.
- Trial name
- NCT05923112
- Where
- Japan
- Volunteers
- 421 people
- Sponsor
- Pfizer
Paroxysmal Atrial Fibrillation
POLARx™ Cardiac Cryoablation System Post Market Clinical Study (POLAR SMART)
This is a post-market study collecting real-world clinical data on safety, effectiveness and procedural success of Boston Scientific Cardiac Cryoablation System (POLARx™ System)
- Trial name
- POLAR SMART (NCT05282823)
- Testing
- Boston Scientific Cardiac Cryoablation System
- Where
- 19 sites in Japan, South Korea
- Volunteers
- 295 people
- Sponsor
- Boston Scientific Corporation
Acute Stroke
IMAS Optimization and Applicability in Acute and Subacute Stroke.
The investigator will investigate our Integrated sensor-based Motion Analysis Suite (IMAS) to objectively and quantitatively measure acute stroke patient motor status.
- Trial name
- NCT05469438
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Case Western Reserve University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.